DGAP-News

MOLOGEN AG: First combination data of TLR9 agonists EnanDIM(R) with checkpoint inhibitor in preclinical tumor models

DGAP-News: MOLOGEN AG / Key word(s): Conference MOLOGEN AG: First combination data of TLR9 agonists EnanDIM(R) with checkpoint inhibitor in preclinical tumor models 27.02.2017 / 10:01 The issuer is solely responsible for the content of this announcement. Press Release N 7 / 2017 of 02/27/2017

MOLOGEN AG: First combination data of TLR9 agonists EnanDIM(R) with checkpoint inhibitor in preclinical tumor models

Berlin, 27 February 2017 - The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first combination data of its TLR9 agonists EnanDIM(R) with a checkpoint inhibitor. EnanDIM(R) is a new family of TLR9 agonists and socalled Immune Surveillance Reactivators (ISR). The preclinical in vivo data showed that EnanDIM(R) can significantly improve the anti-tumor effect of the checkpoint inhibitor anti-PD-1, and thus prolong survival in a murine colon carcinoma tumor model. The beneficial effect of the combination of EnanDIM(R) with anti-PD-1 antibodies compared to each monotherapeutic approach was confirmed in in vitro experiments. These results constitute a first preclinical confirmation of the combination approach of EnanDIM(R) with checkpoint inhibitors in the treatment of cancer.


"We believe that patients can benefit from the combination of these immunotherapeutic approaches due to the fact that their modes of action complement each other. These new results are an important proof-of-concept for the strategy to combine EnanDIM(R) with checkpoint inhibitors. The same is true for our lead compound lefitolimod - we just recently presented the findings at an important international scientific conference. Consequently, the data open further application possibilities for our TLR9 product family", said Dr. Mariola Söhngen, CEO of MOLOGEN AG.

EnanDIM(R) (Enantiomeric, DNA-based, ImmunoModulator), as a new generation of immunomodulators and socalled Immune Surveillance Reactivators (ISR), belongs to the class of TLR9 agonists and represents one of MOLOGEN's follow-up compounds to lefitolimod exhibiting an variable immunomodulatory pattern dependent on the specific EnanDIM(R) molecule, a one-step production process as well as a longer patent protection.